Japan’s regulation of intellectual property combines a technically sophisticated patent system with a judiciary that is generally receptive to well-founded rights. In 2026, we expect that IP will continue to play a central and increasingly integrated role in Japan’s life sciences and health care sector, with further developments in patent practice and enforcement affecting how IP is created, managed, and leveraged.

Generally speaking, Japan’s policy initiatives (e.g., “IP Strategic Program 2025,” innovation-linked tax incentives) increasingly frame IP as a commercial and economic asset. We expect that companies will need to continue to ensure that IP rights are integrated into a broader evidence and value narrative to maximize their potential. As the Japanese government encourages earlier inclusion of drug candidates in global development and faster patient access, we further anticipate a pro-patent enforcement environment, faster examination, and predictable remedies.

Regarding early-stage IP, the recent tightening of inventorship rules and the restriction of post-filing corrections in Japan mean that life sciences companies need to be thoughtful, especially about inventions emerging from collaborative, data-driven environments. We recommend careful documentation of human contribution, particularly as AI tools become embedded in drug discovery, target identification, trial design, and data analysis. In the AI arena in particular, we anticipate greater regulatory emphasis on governance, transparency, and human oversight of AI in Japan – which will in turn affect patentability, inventorship, regulatory credibility, and valuation. Therefore, as in many other countries, we recommend a careful, disciplined, and rigorous approach to companies’ use of AI in R&D.

One potential area of change in the year ahead relates to Fair, Reasonable, and Non-Discriminatory (FRAND) terms, which are licensing commitments by holders of standard essential patents (SEPs) to manufacturers for implementing industry standards. We anticipate that these may increasingly influence life sciences companies at the intersection of digital health, diagnostics, and connected medical devices. There have been recent high profile SEP decisions evincing Japan’s willingness to engage substantively with global licensing disputes, positioning it as an increasingly important forum in cross-border IP strategy.

Lifecycle management will remain critical. Although Japan lacks a formal patent linkage regime, its courts remain receptive to early infringement actions and preliminary injunctions timed to regulatory approval and pricing milestones; based on our experience and recent cases, we anticipate Japanese patent law to change in 2026 in certain related aspects. In practice, this creates de facto linkage, especially for biologics and complex formulations, and it elevates the strategic importance of secondary patents, such as those covering dosing and manufacturing processes.

Taken together, recent IP developments underscore how Japan rewards precision and foresight. We expect patents to remain powerful commercial tools in 2026 and beyond, but companies will need to continue to ensure they are aligned with regulatory timing, evidentiary strategy, and long-term portfolio planning.